222 related articles for article (PubMed ID: 31982960)
1. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Mouri A; Kaira K; Shiono A; Yamaguchi O; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):1005-1008. PubMed ID: 30859745
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
Hata A; Harada D; Okuda C; Kaji R; Masuda Y; Takechi Y; Kozuki T; Nogami N; Katakami N
Oncotarget; 2018 Jun; 9(45):27789-27796. PubMed ID: 29963237
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
[TBL] [Abstract][Full Text] [Related]
9. [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
Yamamoto A; Iwata T
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1421-1425. PubMed ID: 31530782
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).
Tachihara M; Hata A; Tokito T; Hara S; Okada H; Miura S; Sato Y; Tabata E; Watanabe H; Takayama Y; Toyozawa R; Ota K; Wakuda K; Nakamura A; Shimokawa M; Yamamoto N; Nakagawa K
JTO Clin Res Rep; 2023 Oct; 4(10):100569. PubMed ID: 37822699
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Zardawi SJ; Nordman I; Zdenkowski N
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
14. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Garon EB; Winfree KB; Molife C; Cui ZL; Arriola E; Levy B; Mekhail T; Pérol M
Support Care Cancer; 2021 Jan; 29(1):117-125. PubMed ID: 32318871
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
18. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Ishida M; Morimoto K; Yamada T; Shiotsu S; Chihara Y; Yamada T; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Takeda T; Takayama K
Thorac Cancer; 2022 Jan; 13(2):173-181. PubMed ID: 34791812
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB
Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
